Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-HKG301 PET/CT for staging and restaging primary breast cancer (FAPILOUS)
2025-521324-29-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [68Ga]Ga-HKG301 in breast cancer, sponsored by University Hospital Odense. Primary endpoint: Diagnostic performance of [68Ga]Ga-HKG301 PET/CT for staging and restaging breast cancer. Planned start Aug 2026; status: authorised.
02
Drugs
[68Ga]Ga-HKG301
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521324-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521324-29-00.